GCP
RCKT icon

GSA Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

GSA Capital Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,836
Closed -$129K – 2087
2025
Q4 		$129K Sell
36,836
-187,440
-84% -$642K 0.01% 1503
2025
Q3 		$731K Buy
224,276
+187,037
+502% +$589K 0.06% 596
2025
Q2 		$91K Buy
37,239
+12,607
+51% +$63.9K 0.01% 1623
2025
Q1 		$164K Buy
+24,632
New +$243K 0.01% 1439
2022
Q4 		– Sell
-54,582
Closed -$871K – 1815
2022
Q3 		$871K Buy
54,582
+33,293
+156% +$520K 0.12% 220
2022
Q2 		$293K Buy
+21,289
New +$254K 0.04% 840
2022
Q1 		– Sell
-35,704
Closed -$779K – 1756
2021
Q4 		$779K Buy
+35,704
New +$974K 0.1% 328
2021
Q1 		– Sell
-6,699
Closed -$367K – 1416
2020
Q4 		$367K Sell
6,699
-13,767
-67% -$502K 0.06% 630
2020
Q3 		$468K Buy
+20,466
New +$504K 0.08% 431
2018
Q1 		– Sell
-3,325
Closed -$35K – 1782
2017
Q4 		$35K Sell
3,325
-88,500
-96% -$877K ﹤0.01% 1511
2017
Q3 		$654K Buy
91,825
+52,750
+135% +$241K 0.04% 793
2017
Q2 		$297K Buy
39,075
+1,625
+4% +$12.1K 0.02% 1282
2017
Q1 		$300K Buy
+37,450
New +$252K 0.02% 1384

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GSA Capital Partners's RCKT Position: Q1 2026 in Review

GSA Capital Partners sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 36,836 shares — an estimated $129K sold.

GSA Capital Partners first reported a position in RCKT in Q1 2017 and held it in 13 quarters. The position peaked at $871K in Q3 2022. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • GSA Capital Partners reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 36,836 Rocket Pharmaceuticals shares in Q1 2026, an estimated $129K.
  • GSA Capital Partners first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 13 quarters.
  • GSA Capital Partners's Rocket Pharmaceuticals position peaked at $871K in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.